Green Cross Pharmaceutical intends to
expand capacity of injection, in order to improve its market share. In
particular, the amino acid injection is its leading product to be promoted.
Source: Internet
Senior executives of Guangzhou Green Cross
Pharmaceutical Co., Ltd. (Green Cross Pharmaceutical) said that the company will
invest USD16.34 million (RMB100 million) in reconstructing its existing
production lines. Besides, the company will also build a large infusion
production line and a small injection production line. At present, the capacity
of Green Cross Pharmaceutical is rather low and its full production is only
less than 20 million bottles per year. After the reconstruction is completed,
its production capacity will reach 50 million bottles per year.
Green Cross Pharmaceutical is mainly
engaged in the production of amino acid injections and lipid emulsion
injections. Among them, four amino acid injections are invented drugs: compound
amino acid injection(18AA)-named Lv'an, therapeutic compound amino acid
injection (18AAⅦ)-named Luzhian, compound amino acid injection for liver diseases
(17AA-H)-named Lvgan'an and compound amino acid injection for kidney diseases
(18AA-Ⅸ)-named Lvshen'an. Specifically, the Lv'an Series (18AA) also get
the pricing power entitled by the government.
The products of Green Cross Pharmaceutical
were not only sold in China, but also 11 Asian and European countries. In 2013,
the company achieved in total of USD16.34 million (RMB 100 million) in output
value. Considering that parentaral nutrition presents bright prospects, Green
Cross Pharmaceutical will invest more in the production of high-end parenteral
nutrition in 2015. At present, the total market size of nutritional drugs
reaches USD3.27 billion (RMB20 billion) in Chinese market, among them,
parenteral nutrition accounts for 80% of the market share. Starting from 2015,
Green Cross Pharmaceutical plans to increase its annual sales to USD81.71
million (RMB500 million) within 3 years and USD163.42 million (RMB1 billion)
within 5 years, making full preparations for getting listed. It means that the
company will continue to expand its capacity to capture more market share in
injection market.
It is noted that the competition in
domestic injection market is becoming more intense, along with the deepening
medical reform. The total domestic market value of amino acid injection reached
over USD0.82 billion (RMB5 billion) in 2014. Green Cross Pharmaceutical only
took up 2% of the market share even through it is one of the top 10 amino acid
injection manufacturers in sales. In recent years, Sichuan Kelun Pharmaceutical
Co., Ltd grow very fast by relying on the capital market. Besides, Hubei Bafeng
Pharmaceutical Co., Ltd., Anhui BBCA Pharmaceuticals Co., Ltd., Yichang Sanxia
Pharmaceutical Co., Ltd, Guangzhou Qiaoguang Pharmaceutical Co., Ltd. and
Jiangsu Dingye Bio-chemical Pharmaceutical Co., Ltd. all entered into amino
acid injection market.
Green Cross Pharmaceutical, originally
named Mitsubishi Pharma (Guangzhou) Co., Ltd., was a wholly owned subsidiary of
Mitsubishi Tanabe Pharma Coporation. In the fourth quarter of 2014, Mitsubishi
Tanabe Pharma Coporation started to adjust its medical business and shift its
focus from small molecule drugs to biopharmaceuticals and medical services. As
a result, the factories of Mitsubishi Pharma (Guangzhou) Co.,Ltd. was sold.
And, Guangdong Shuaiguang Phamaceutical Co.,Ltd. acquired it and renamed it as
Green Cross Pharmaceutical Co., Ltd.
About CCM:
CCM is the leading market intelligence provider for China’s
agriculture, chemicals, food & ingredients and life science markets. Founded in 2001, CCM offers a
range of data and content solutions, from price and trade data to industry
newsletters and customized market research reports. Our clients include Monsanto,
DuPont, Shell, Bayer, and Syngenta. CCM is a brand of Kcomber Inc.
For more
information about CCM, please visit www.cnchemicals.com or get in touch with us
directly by emailing econtact@cnchemicals.com or calling
+86-20-37616606.